Barclays lowered the firm’s price target on Addus HomeCare (ADUS) to $102 from $112 and keeps an Underweight rating on the shares. The firm revised models in the healthcare facilities and managed care group following the Q4 reports.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADUS:
- Balanced Risk Amid Regulatory Overhang: Why Sean Dodge Maintains a Hold on Addus Despite Solid Operational Execution
- Addus HomeCare price target lowered to $135 from $140 at Stephens
- Addus HomeCare Earnings Call Highlights Growth And Scale
- Addus HomeCare falls -12.4%
- Addus HomeCare price target lowered to $112 from $117 at Barclays